Table 1.
Patients’ Characteristics.
| Total Group (n = 168) |
Naïve Group (n = 56) |
Switch Group (n = 112) |
p (Naïve vs. Switch) |
|
|---|---|---|---|---|
| Age (years) | 61 ± 14 | 64 ± 14 | 59 ± 14 | 0.04 |
| Male (%) | 57 | 52 | 60 | 0.32 |
| Dialysis vintage (month) | 58 (IQR 32–102) | 35 (IQR 14–63) | 69 (IQR 48–120) | <0.001 |
| Diabetes (%) | 25 | 31 | 22 | 0.23 |
| Cardiovascular comorbidities (%) | 73 | 70 | 75 | 0.53 |
| iPTH (pg/ml) | 636 (IQR 493–916) | 602 (IQR 509–800) | 664 (IQR 495–947) | 0.67 |
| Serum Calcium (mEq/L) | 9.0 ± 1.0 | 9.1 ± 0.7 | 9.0 ± 1.1 | 0.60 |
| Serum Phosphate (mg/dL) | 5.6 ± 1.4 | 5.5 ± 1.4 | 5.6 ± 1.4 | 0.83 |
| Alkaline Phosphate (U.I./L) | 131 (IQR 83–201) | 111 (IQR 74–159) | 148 (IQR 88–221) | 0.02 |
| Hb (gr/dL) | 11.1 ± 1.4 | 11.0 ± 1.2 | 11.1 ± 1.4 | 0.58 |
| ESA treatment (%) | 87 | 88 | 87 | 0.97 |
| Phosphate binders therapy (%) | 96 | 93 | 97 | 0.17 |
| Calcium containing binders (%) | 18 | 25 | 14 | 0.09 |
| Vitamin D therapy (%) | 75 | 83 | 71 | 0.09 |
| Native Vitamin D therapy (%) | 5 | 4 | 6 | 0.59 |
| Previous cinacalcet treatment (%) | 67 | 0 | 100 | N/A |
IQR, interquartile range; iPTH, intact parathyroid hormone; Hb, hemoglobin; ESA, erythropoietin-stimulating agent.